The transition metals copper and iron in neurodegenerative diseases

Chemico-Biological Interactions

Volumn 186, Issue 2, 2010, Pages 184-199

  Rivera Mancía, Susana ^a   Pérez Neri, Iván ^a   Ríos, Camilo ^a   Tristán López, Luis ^a   Rivera Espinosa, Liliana ^b   Montes, Sergio ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Copper; Huntington's disease; Iron; Parkinson's disease

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; BETA LACTAM ANTIBIOTIC; CHELATING AGENT; CLIOQUINOL; COPPER; COPPER CHELATING AGENT; COPPER COMPLEX; CURCUMIN; DEFERIPRONE; DEFEROXAMINE; DIETHYLDITHIOCARBAMIC ACID; EPIGALLOCATECHIN GALLATE; FREE RADICAL; GINKGO BILOBA EXTRACT; GLYOXALBIS(N4 METHYL 3 THIOSEMICARBAZONATO)COPPER COMPLEX; HLA 20; IRON; IRON CHELATING AGENT; PENICILLAMINE; PLACEBO; PYRROLIDINE DITHIOCARBAMATE; SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; TETRATHIOMOLYBDATE AMMONIUM; TRANSITION ELEMENT; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOACCUMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; COPPER METABOLISM; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG PENETRATION; FENTON REACTION; FRIEDREICH ATAXIA; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; IRON METABOLISM; METAL BINDING; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN INTERACTION; REVIEW; SENILE PLAQUE; TRACE METAL BLOOD LEVEL; TRINUCLEOTIDE REPEAT; WILSON DISEASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CARRIER PROTEINS; CHELATING AGENTS; COPPER; HOMEOSTASIS; HUMANS; HUNTINGTON DISEASE; IRON; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 77953541514     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.04.010     Document Type: Review

References (253)

1. Gaeta A., Hider R.C. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 2005, 146:1041-1059.
2. Levenson C.W. Trace metal regulation of neuronal apoptosis: from genes to behavior. Physiol. Behav. 2005, 86:399-406.
3. Price D.L. New order from neurological disorders. Nature 1999, 399:A3-A5.
4. Rottkamp C.A., Nunomura A., Hirai K., Sayre L.M., Perry G., Smith M.A. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease?. Mech. Ageing Dev. 2000, 116:169-179.
5. Youdim M.B., Fridkin M., Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. 2005, 126:317-326.
6. Beard J.L., Connor J.R. Iron status and neural functioning. Annu. Rev. Nutr. 2003, 23:41-58.
7. Ponka P. Cellular iron metabolism. Kidney Int. Suppl. 1999, 69:S2-11.
8. Peña M.M., Lee J., Thiele D.J. A delicate balance: homeostatic control of copper uptake and distribution. J. Nutr. 1999, 129:1251-1260.
9. Connor J.R., Benkovic S.A. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann. Neurol. 1992, 32(Suppl.):S51-S61.
10. Rouault T.A. Systemic iron metabolism: a review and implications for brain iron metabolism. Pediatr. Neurol. 2001, 25:130-137.
11. Berg D., Youdim M.B. Role of iron in neurodegenerative disorders. Top. Magn. Reson. Imag. 2006, 17:5-17.
12. Dexter D.T., Jenner P., Schapira A.H., Marsden C.D. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 1992, 32(Suppl.):S94-100.
13. Simmons D.A., Casale M., Alcon B., Pham N., Narayan N., Lynch G. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007, 55:1074-1084.
14. Aruoma O.I., Kaur H., Halliwell B. Oxygen free radicals and human diseases. J. R. Soc. Health 1991, 111:172-177.
15. Agar J., Durham H. Relevance of oxidative injury in the pathogenesis of motor neuron diseases. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003, 4:232-242.
16. Madsen E., Gitlin J.D. Copper and iron disorders of the brain. Annu. Rev. Neurosci. 2007, 30:317-337.
17. Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., Hediger M.A. Cloning and characterization of a mammalian protein-coupled metal-ion transporter. Nature 1997, 388:482-488.
18. Kelley B.J., Petersen R.C. Alzheimer's disease and mild cognitive impairment. Neurol. Clin. 2007, 25:577-609.
19. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Alzheimer's Disease International, global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
20. Jellinger K.A., Bancher C. Neuropathology of Alzheimer's disease: a critical update. J. Neural Transm. Suppl. 1998, 54:77-95.
21. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985, 4:2757-2763.
22. Eckman C.B., Eckman E.A. An update on the amyloid hypothesis. Neurol. Clin. 2007, 25:669-682.
23. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
24. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A., St George-Hyslop P., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., Neve R.L. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-884.
25. Jarrett J.T., Berger E.P., Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
26. Prelli F., Castano E.M., van Duinen S.G., Bots G.T., Luyendijk W., Frangione B. Different processing of Alzheimer's beta-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem. Biophys. Res. Commun. 1988, 151:1150-1155.
27. Crouch P.J., White A.R., Bush A.I. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J. 2007, 274:3775-3783.
28. Liu G., Huang W., Moir R.D., Vanderburg C.R., Lai B., Peng Z., Tanzi R.E., Rogers J.T., Huang X. Metal exposure and Alzheimer's pathogenesis. J. Struct. Biol. 2006, 155:45-51.
29. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 1998, 158:47-52.
30. Barnham K.J., Haeffner F., Ciccotosto G.D., Curtain C.C., Tew D., Mavros C., Beyreuther K., Carrington D., Masters C.L., Cherny R.A., Cappai R., Bush A.I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 2004, 18:1427-1429.
31. Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38:7609-7616.
32. Schubert D., Chevion M. The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 1995, 216:702-707.
33. Moalem S., Percy M.E., Andrews D.F., Kruck T.P., Wong S., Dalton A.J., Mehta P., Fedor B., Warren A.C. Are hereditary hemochromatosis mutations involved in Alzheimer disease?. Am. J. Med. Genet. 2000, 93:58-66.
34. Rogers J.T., Randall J.D., Cahill C.M., Eder P.S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S.S., Utsuki T., Greig N.H., Lahiri D.K., Tanzi R.E., Bush A.I., Giordano T., Gullans S.R. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277:45518-45528.
35. Robinson S.R., Noon D.F., Kril J., Halliday G. Most amyloid plaques contain ferritin rich cells. Alz. Res. 1995, 1:191-196.
36. Ding B., Chen K.M., Ling H.W., Sun F., Li X., Wan T., Chai W.M., Zhang H., Zhan Y., Guan Y.J. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J. Magn. Reson. Imag. 2009, 29:793-798.
37. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
38. Kitazawa M., Cheng D., LaFerla F.M. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J. Neurochem. 2009, 108:1550-1560.
39. Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., Tanzi R.E., Bush A.I. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 2000, 75:1219-1233.
40. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., Bush A.I. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 1999, 274:37111-37116.
41. Opazo C., Huang X., Cherny R.A., Moir R.D., Roher A.E., White A.R., Cappai R., Masters C.L., Tanzi R.E., Inestrosa N.C., Bush A.I. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 2002, 277:40302-40308.
42. Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., Wilson J.M., DiStefano L.M., Nobrega J.N. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 1992, 59:776-779.
43. Crouch P.J., Barnham K.J., Duce J.A., Blake R.E., Masters C.L., Trounce I.A. Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J. Neurochem. 2006, 99:226-236.
44. Crouch P.J., Blake R., Duce J.A., Ciccotosto G.D., Li Q.X., Barnham K.J., Curtain C.C., Cherny R.A., Cappai R., Dyrks T., Masters C.L., Trounce I.A. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 2005, 25:672-679.
45. Schlief M.L., Craig A.M., Gitlin J.D. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J. Neurosci. 2005, 25:239-246.
46. White A.R., Reyes R., Mercer J.F., Camakaris J., Zheng H., Bush A.I., Multhaup G., Beyreuther K., Masters C.L., Cappai R. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 1999, 842:439-444.
47. Squitti R., Pasqualetti P., Dal F.G., Moffa F., Cassetta E., Lupoi D., Vernieri F., Rossi L., Baldassini M., Rossini P.M. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005, 64:1040-1046.
48. Squitti R., Barbati G., Rossi L., Ventriglia M., Dal F.G., Cesaretti S., Moffa F., Caridi I., Cassetta E., Pasqualetti P., Calabrese L., Lupoi D., Rossini P.M. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 2006, 67:76-82.
49. Bellingham S.A., Lahiri D.K., Maloney B., La Fontaine S., Multhaup G., Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J. Biol. Chem. 2004, 279:20378-20386.
50. Strozyk D., Launer L.J., Adlard P.A., Cherny R.A., Tsatsanis A., Volitakis I., Blennow K., Petrovitch H., White L.R., Bush A.I. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol. Aging 2009, 30:1069-1077.
51. Adamson I.Y., Vincent R., Bakowska J. Differential production of metalloproteinases after instilling various urban air particle samples to rat lung. Exp. Lung Res. 2003, 29:375-388.
52. Wu W., Samet J.M., Silbajoris R., Dailey L.A., Sheppard D., Bromberg P.A., Graves L.M. Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. Am. J. Respir. Cell Mol. Biol. 2004, 30:540-547.
53. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 2006, 281:17670-17680.
54. Borchardt T., Camakaris J., Cappai R., Masters C.L., Beyreuther K., Multhaup G. Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem. J. 1999, 344(Pt. 2):461-467.
55. Cater M.A., McInnes K.T., Li Q.X., Volitakis I., La F.S., Mercer J.F., Bush A.I. Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms. Biochem. J. 2008, 412:141-152.
56. Boll M.C., Alcaraz-Zubeldia M., Montes S., Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem. Res. 2008, 33:1717-1723.
57. Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21:455-462.
58. Texel S.J., Xu X., Harris Z.L. Ceruloplasmin in neurodegenerative diseases. Biochem. Soc. Trans. 2008, 36:1277-1281.
59. Loeffler D.A., LeWitt P.A., Juneau P.L., Sima A.A., Nguyen H.U., DeMaggio A.J., Brickman C.M., Brewer G.J., Dick R.D., Troyer M.D., Kanaley L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 1996, 738:265-274.
60. Connor J.R., Tucker P., Johnson M., Snyder B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci. Lett. 1993, 159:88-90.
61. Avramovich-Tirosh Y., Amit T., Bar-Am O., Zheng H., Fridkin M., Youdim M.B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 2007, 100:490-502.
62. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., Ehrhart J., Townsend K., Zeng J., Morgan D., Hardy J., Town T., Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 2005, 25:8807-8814.
63. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M.B., Weinreb O., Mandel S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. 2006, 97:527-536.
64. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
65. Baum L., Lam C.W., Cheung S.K., Kwok T., Lui V., Tsoh J., Lam L., Leung V., Hui E., Ng C., Woo J., Chiu H.F., Goggins W.B., Zee B.C., Cheng K.F., Fong C.Y., Wong A., Mok H., Chow M.S., Ho P.C., Ip S.P., Ho C.S., Yu X.W., Lai C.Y., Chan M.H., Szeto S., Chan I.H., Mok V. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 2008, 28:110-113.
66. Blat D., Weiner L., Youdim M.B., Fridkin M. A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. J. Med. Chem. 2008, 51:126-134.
67. Boddaert N., Le Quang Sang K.H., Rötig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J.C., Munnich A., Cabantchik Z.I. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
68. Liu G., Men P., Harris P.L., Rolston R.K., Perry G., Smith M.A. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 2006, 406:189-193.
69. Liu G., Men P., Kudo W., Perry G., Smith M.A. Nanoparticle-chelator conjugates as inhibitors of amyloid-aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci. Lett. 2009, 455:187-190.
70. Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 1999, 274:23223-23228.
71. Squitti R., Rossini P.M., Cassetta E., Moffa F., Pasqualetti P., Cortesi M., Colloca A., Rossi L., Finazzi-Agro A. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur. J. Clin. Invest. 2002, 32:51-59.
72. Malm T.M., Iivonen H., Goldsteins G., Keksa-Goldsteine V., Ahtoniemi T., Kanninen K., Salminen A., Auriola S., Van G.T., Tanila H., Koistinaho J. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J. Neurosci. 2007, 27:3712-3721.
73. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
74. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60:1685-1691.
75. Schäfer S., Pajonk F.G., Multhaup G., Bayer T.A. Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels. J. Mol. Med. 2007, 85:405-413.
76. Donnelly P.S., Caragounis A., Du T., Laughton K.M., Volitakis I., Cherny R.A., Sharples R.A., Hill A.F., Li Q.X., Masters C.L., Barnham K.J., White A.R. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J. Biol. Chem. 2008, 283:4568-4577.
77. Crouch P.J., Hung L.W., Adlard P.A., Cortes M., Lal V., Filiz G., Perez K.A., Nurjono A., Caragounis A., Du T., Laughton K.M., Volitakis I., Bush A.I., Li Q.X., Masters C.L., Cappai R., Cherny R.A., Donnelly P.S., White A.R., Barnham K.J. Increasing Cu bioavailability inhibits A oligomers and tau phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:381-386.
78. Bolognesi M.L., Cavalli A., Valgimigli L., Bartolini M., Rosini M., Andrisano V., Recanatini M., Melchiorre C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem. 2007, 50:6446-6449.
79. Bharath S., Hsu M., Kaur D., Rajagopalan S., Andersen J.K. Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 2002, 64:1037-1048.
80. Barlow B.K., Cory-Slechta D.A., Richfield E.K., Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod. Toxicol. 2007, 23:457-470.
81. Kaur D., Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease?. Ageing Res. Rev. 2004, 3:327-343.
82. Burn D.J., Tröster A.I. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr. Psychiatry Neurol. 2004, 17:172-180.
83. Rees P.M., Fowler C.J., Maas C.P. Sexual function in men and women with neurological disorders. Lancet 2007, 369:512-525.
84. Graumann R., Paris I., Martinez-Alvarado P., Rumanque P., Perez-Pastene C., Cardenas S.P., Marin P., Diaz-Grez F., Caviedes R., Caviedes P., Segura-Aguilar J. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase. Pol. J. Pharmacol. 2002, 54:573-579.
85. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 2005, 64:2021-2028.
86. Gorell J.M., Peterson E.L., Rybicki B.A., Johnson C.C. Multiple risk factors for Parkinson's disease. J. Neurol. Sci. 2004, 217:169-174.
87. Götz M.E., Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 2004, 1012:193-208.
88. Castellanos M., Puig N., Carbonell T., Castillo J., Martinez J., Rama R., Dávalos A. Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats. Brain Res. 2002, 952:1-6.
89. Cheah J.H., Kim S.F., Hester L.D., Clancy K.W., Patterson S.E., Papadopoulos V., Snyder S.H. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 2006, 51:431-440.
90. Double K.L., Halliday G.M., Henderson J., Griffiths F.M., Heinemann T., Riederer P., Gerlach M. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp. Neurol. 2003, 184:530-535.
91. Behnke S., Berg D., Becker G. Does ultrasound disclose a vulnerability factor for Parkinson's disease?. J. Neurol. 2003, 250(Suppl. 1):I24-I27.
92. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 1989, 52:1830-1836.
93. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68:1820-1825.
94. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 1989, 52:515-520.
95. Becker G., Berg D. Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. Mov. Disord. 2001, 16:23-32.
96. R. Martínez-Hernandez, S. Montes, J. Higuera-Calleja, P. Yescas, M.C. Boll, C. Rios, Plasma ceruloplasmin ferroxidase activity correlates with nigral sonographic area. 2010, unpublished results.
97. Berg D., Roggendorf W., Schroder U., Klein R., Tatschner T., Benz P., Tucha O., Preier M., Lange K.W., Reiners K., Gerlach M., Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 2002, 59:999-1005.
98. Vymazal J., Righini A., Brooks R.A., Canesi M., Mariani C., Leonardi M., Pezzoli G. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999, 211:489-495.
99. Brar S., Henderson D., Schenck J., Zimmerman E.A. Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. Arch. Neurol. 2009, 66:371-374.
100. Cass W.A., Grondin R., Andersen A.H., Zhang Z., Hardy P.A., Hussey-Andersen L.K., Rayens W.S., Gerhardt G.A., Gash D.M. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiol. Aging 2007, 28:258-271.
101. Brown G.C., Borutaite V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 2004, 1658:44-49.
102. Hadziahmetovic M., Dentchev T., Song Y., Haddad N., He X., Hahn P., Pratico D., Wen R., Harris Z.L., Lambris J.D., Beard J., Dunaief J.L. Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest. Ophthalmol. Vis. Sci. 2008, 49:2728-2736.
103. Wang J., Jiang H., Xie J.X. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur. J. Neurosci. 2007, 25:2766-2772.
104. Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., Zeiler B., Bornemann A., Pahnke J., Becker G., Riess O., Berg D. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004, 63:1912-1917.
105. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L.M., Nuñez M.T., Garrick M.D., Raisman-Vozari R., Hirsch E.C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18578-18583.
106. Zhang S., Wang J., Song N., Xie J., Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in MES23.5 cells. Neurobiol. Aging 2009, 30:1466-1476.
107. Maharaj D.S., Maharaj H., Daya S., Glass B.D. Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity. J. Neurochem. 2006, 96:78-81.
108. Muller A.C., Dairam A., Limson J.L., Daya S. Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sci. 2007, 80:918-925.
109. Mendez-Alvarez E., Soto-Otero R., Hermida-Ameijeiras A., Lopez-Martin M.E., Labandeira-Garcia J.L. Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants. Free Radic. Biol. Med. 2001, 31:986-998.
110. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53 T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 2000, 20:6048-6054.
111. Gupta A., Dawson V.L., Dawson T.M. What causes cell death in Parkinson's disease?. Ann. Neurol. 2008, 64(Suppl.):S3-S15.
112. Kaur D., Peng J., Chinta S.J., Rajagopalan S., Di Monte D.A., Cherny R.A., Andersen J.K. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol. Aging 2007, 28:907-913.
113. Fredriksson A., Archer T. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration. Behav. Brain Res. 2003, 139:31-46.
114. Aguirre P., Valdés P., Aracena-Parks P., Tapia V., Núñez M.T. Upregulation of -glutamate-cysteine ligase as part of the long-term adaptation process to iron accumulation in neuronal. Am. J. Physiol. Cell Physiol. 2007, 292:C2197-C2203.
115. Arredondo M., Núñez M.T. Iron and copper metabolism. Mol. Aspects Med. 2005, 26:313-327.
116. Popescu B.F., George M.J., Bergmann U., Garachtchenko A.V., Kelly M.E., McCrea R.P.E., Lüning K., Devon R.M., George G.N., Hanson A.D., Harder S.M., Chapman L.D., Pickering I.J., Nichol H. Mapping metals in Parkinson's and normal brain using rapid-scanning X-ray fluorescence. Phys. Med. Biol. 2009, 54:651-653.
117. Beshgetoor D., Hambidge M. Clinical conditions altering copper metabolism in humans. Am. J Clin. Nutr. 1998, 67:1017S-1021S.
118. Boll M.C., Sotelo J., Otero E., Alcaraz-Zubeldia M., Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci. Lett. 1999, 265:155-158.
119. Rasia R.M., Bertoncini C.W., Marsh D., Hoyer W., Cherny D., Zweckstetter M., Griesinger C., Jovin T.M., Fernandez C.O. Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4294-4299.
120. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276:44284-44296.
121. 2. J. Neurochem. 2003, 84:1128-1142.
122. Paik S.R., Shin H.J., Lee J.H. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. Arch. Biochem. Biophys. 2000, 378:269-277.
123. Kim K.S., Choi S.Y., Kwon H.Y., Won M.H., Kang T.C., Kang J.H. The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. Biochimie 2002, 84:625-631.
124. Lowe R., Pountney D.L., Jensen P.H., Gai W.P., Voelcker N.H. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 2004, 13:3245-3252.
125. Wang X.F., Cynader M.S. Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity. J. Neurosci. 2001, 21:3322-3331.
126. Sun S.H., O'Dell B.L. Low copper status of rats affects polyunsaturated fatty acid composition of brain phospholipids, unrelated to neuropathology. J. Nutr. 1992, 122:65-73.
127. + neurotoxicity in mice. Neurochem. Res. 2001, 26:59-64.
128. + in rats. Neurochem. Int. 2009, 54:447-451.
129. Santamaria A., Flores-Escartin A., Martinez J.C., Osorio L., Galvan-Arzate S., Pedraza-Chaverri J., Maldonado P.D., Medina-Campos O.N., Jimenez-Capdeville M.E., Manjarrez J., Rios C. Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems. Free Radic. Biol. Med. 2003, 35:418-427.
130. Youdim M.B., Grunblatt E., Mandel S. The copper chelator, d-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. J. Neural Transm. 2007, 114:205-209.
131. Rios C., Alvarez-Vega R., Rojas P. Depletion of copper and manganese in brain after MPTP treatment of mice. Pharmacol. Toxicol. 1995, 76:348-352.
132. Aguirre P., Mena N., Tapia V., Arredondo M., Núñez M.T. Iron homeostasis in neuronal cells: a role for IREG1. BMC Neurosci. 2005, 6:3.
133. Aigner E., Theurl I., Haufe H., Seifert M., Hohla F., Scharinger L., Stickel F., Mourlane F., Weiss G., Datz C. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008, 135:680-688.
134. Auclair S., Feillet-Coudray C., Coudray C., Schneider S., Muckenthaler M.U., Mazur A. Mild copper deficiency alters gene expression of proteins involved in iron metabolism. Blood Cells Mol. Dis. 2006, 36:15-20.
135. Das D., Tapryal N., Goswami S.K., Fox P.L., Mukhopadhyay C.K. Regulation of ceruloplasmin in human hepatic cells by redox active copper: identification of a novel AP-1 site in the ceruloplasmin gene. Biochem. J. 2007, 402:135-141.
136. De Domenico I., Ward D.M., di Patti M.C., Jeong S.Y., David S., Musci G., Kaplan J. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007, 26:2823-2831.
137. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
138. Shang T., Kotamraju S., Kalivendi S.V., Hillard C.J., Kalyanaraman B. 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide. J. Biol. Chem. 2004, 279:19099-19112.
139. Johnson C.C., Gorell J.M., Rybicki B.A., Sanders K., Peterson E.L. Adult nutrient intake as a risk factor for Parkinson's disease. Int. J. Epidemiol. 1999, 28:1102-1109.
140. Levenson C.W., Cutler R.G., Ladenheim B., Cadet J.L., Hare J., Mattson M.P. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp. Neurol. 2004, 190:506-514.
141. Rojas P., Montes S., Serrano-García N., Rojas-Castañeda J. Effect of EGb761 supplementation on the content of copper in mouse brain in an animal model of Parkinson's disease. Nutrition 2009, 25:482-485.
142. Siciliano G., Piazza S., Carlesi C., Del C.A., Franzini M., Pompella A., Malvaldi G., Mancuso M., Paolicchi A., Murri L. Antioxidant capacity and protein oxidation in cerebrospinal fluid of amyotrophic lateral sclerosis. J. Neurol. 2007, 254:575-580.
143. Orth M., Schapira A.H. Mitochondria and degenerative disorders. Am. J. Med. Genet. 2001, 106:27-36.
144. Andersen P.M. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr. Neurol. Neurosci. Rep. 2006, 6:37-46.
145. Banci L., Bertini I., Durazo A., Girotto S., Gralla E.B., Martinelli M., Valentine J.S., Vieru M., Whitelegge J.P. Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: a possible general mechanism for familial ALS. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11263-11267.
146. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
147. Reaume A.G., Elliott J.L., Hoffman E.K., Kowall N.W., Ferrante R.J., Siwek D.F., Wilcox H.M., Flood D.G., Beal M.F., Brown R.H., Scott R.W., Snider W.D. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 1996, 13:43-47.
148. Okamoto K., Hirai S., Amari M., Watanabe M., Sakurai A. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci. Lett. 1993, 162:125-128.
149. Leigh P.N., Anderton B.H., Dodson A., Gallo J.M., Swash M., Power D.M. Ubiquitin deposits in anterior horn cells in motor neurone disease. Neurosci. Lett. 1988, 93:197-203.
150. Kato T., Katagiri T., Hirano A., Kawanami T., Sasaki H. Lewy body-like hyaline inclusions in sporadic motor neuron disease are ubiquitinated. Acta Neuropathol. 1989, 77:391-396.
151. Matsumoto S., Kusaka H., Ito H., Shibata N., Asayama T., Imai T. Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase-positive Lewy body-like inclusions. Clin. Neuropathol. 1996, 15:41-46.
152. Deng H.X., Shi Y., Furukawa Y., Zhai H., Fu R., Liu E., Gorrie G.H., Khan M.S., Hung W.Y., Bigio E.H., Lukas T., Dal Canto M.C., O'Halloran T.V., Siddique T. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7142-7147.
153. Danzeisen R., Achsel T., Bederke U., Cozzolino M., Crosio C., Ferri A., Frenzel M., Gralla E.B., Huber L., Ludolph A., Nencini M., Rotilio G., Valentine J.S., Carrì M.T. Superoxide dismutase 1 modulates expression of transferrin receptor. J. Biol. Inorg. Chem. 2006, 11:489-498.
154. Banci L., Bertini I., Boca M., Girotto S., Martinelli M., Valentine J.S., Vieru M. SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. PLoS ONE 2008, 3:e1677.
155. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1998, 1366:211-223.
156. Ince P.G., Shaw P.J., Candy J.M., Mantle D., Tandon L., Ehmann W.D., Markesbery W.R. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci. Lett. 1994, 182:87-90.
157. Kasarskis E.J., Tandon L., Lovell M.A., Ehmann W.D. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J. Neurol. Sci. 1995, 130:203-208.
158. Leveugle B., Spik G., Perl D.P., Bouras C., Fillit H.M., Hof P.R. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res. 1994, 650:20-31.
159. Olsen M.K., Roberds S.L., Ellerbrock B.R., Fleck T.J., McKinley D.K., Gurney M.E. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann. Neurol. 2001, 50:730-740.
160. Jeong S.Y., Rathore K.I., Schulz K., Ponka P., Arosio P., David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2009, 29:610-619.
161. Mizuno Y., Amari M., Takatama M., Aizawa H., Mihara B., Okamoto K. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol. 2006, 112:597-603.
162. Okamoto K., Mizuno Y., Fujita Y. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 2008, 28:109-115.
163. Wang X.S., Lee S., Simmons Z., Boyer P., Scott K., Liu W., Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J. Neurol. Sci. 2004, 227:27-33.
164. Fleming R.E., Sly W.S. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu. Rev. Physiol. 2002, 64:663-680.
165. Stendel R., Pietila T.A., Lehmann K., Kurth R., Suess O., Brock M. Ruptured intracranial dermoid cysts. Surg. Neurol. 2002, 57:391-398.
166. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Res. Bull. 2001, 55:155-164.
167. Kapaki E., Zournas C., Kanias G., Zambelis T., Kakami A., Papageorgiou C. Essential trace element alterations in amyotrophic lateral sclerosis. J. Neurol. Sci. 1997, 147:171-175.
168. Ahtoniemi T., Goldsteins G., Keksa-Goldsteine V., Malm T., Kanninen K., Salminen A., Koistinaho J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol. Pharmacol. 2007, 71:30-37.
169. Li Q.X., Mok S.S., Laughton K.M., McLean C.A., Volitakis I., Cherny R.A., Cheung N.S., White A.R., Masters C.L. Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell 2006, 5:153-165.
170. Tokuda E., Ono S., Ishige K., Naganuma A., Ito Y., Suzuki T. Metallothionein proteins expression, copper and zinc concentrations, and lipid peroxidation level in a rodent model for amyotrophic lateral sclerosis. Toxicology 2007, 229:33-41.
171. Tokuda E., Ono S., Ishige K., Watanabe S., Okawa E., Ito Y., Suzuki T. Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp. Neurol. 2008, 213:122-128.
172. Jonsson P.A., Graffmo K.S., Andersen P.M., Brännström T., Lindberg M., Oliveberg M., Marklund S.L. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 2006, 129:451-464.
173. Hayward L.J., Rodriguez J.A., Kim J.W., Tiwari A., Goto J.J., Cabelli D.E., Valentine J.S., Brown R.H. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 2002, 277:15923-15931.
174. Valentine J.S., Hart P.J., Misfolded CuZnSOD and amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3617-3622.
175. Hart P.J. Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr. Opin. Chem. Biol. 2006, 10:131-138.
176. Martyshkin D.V., Mirov S.B., Zhuang Y.X., Crow J.P., Ermilov V., Beckman J.S. Fluorescence assay for monitoring Zn-deficient superoxide dismutase in vitro. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2003, 59:3165-3175.
177. Estévez A.G., Crow J.P., Sampson J.B., Reiter C., Zhuang Y., Richardson G.J., Tarpey M.M., Barbeito L., Beckman J.S. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999, 286:2498-2500.
178. Goto J.J., Gralla E.B., Valentine J.S., Cabelli D.E. Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper-zinc superoxide dismutases studied by pulse radiolysis. J. Biol. Chem. 1998, 273:30104-30109.
179. Oztug Durer Z.A., Cohlberg J.A., Dinh P., Padua S., Ehrenclou K., Downes S., Tan J.K., Nakano Y., Bowman C.J., Hoskins J.L., Kwon C., Mason A.Z., Rodriguez J.A., Doucette P.A., Shaw B.F., Valentine J.S. Loss of metal ions, disulfide reduction and mutations related to familial ALS promote formation of amyloid-like aggregates from superoxide dismutase. PLoS ONE 2009, 4:e5004.
180. Furukawa Y., O'Halloran T.V. Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J. Biol. Chem. 2005, 280:17266-17274.
181. Arnesano F., Banci L., Bertini I., Martinelli M., Furukawa Y., O'Halloran T.V. The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J. Biol. Chem. 2004, 279:47998-48003.
182. Niwa J., Yamada S., Ishigaki S., Sone J., Takahashi M., Katsuno M., Tanaka F., Doyu M., Sobue G. Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. J. Biol. Chem. 2007, 282:28087-28095.
183. Doucette P.A., Whitson L.J., Cao X., Schirf V., Demeler B., Valentine J.S., Hansen J.C., Hart P.J. Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. Insights into the molecular basis for dimer stability. J. Biol. Chem. 2004, 279:54558-54566.
184. Lindberg M.J., Normark J., Holmgren A., Oliveberg M. Folding of human superoxide dismutase: disulfide reduction prevents dimerization and produces marginally stable monomers. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15893-15898.
185. Kurahashi T., Miyazaki A., Suwan S., Isobe M. Extensive investigations on oxidized amino acid residues in H(2)O(2)-treated Cu,Zn-SOd protein with LC-ESI-Q-TOF-MS, MS/MS for the determination of the copper-binding site. J. Am. Chem. Soc. 2001, 123:9268-9278.
186. Roberts B.R., Tainer J.A., Getzoff E.D., Malencik D.A., Anderson S.R., Bomben V.C., Meyers K.R., Karplus P.A., Beckman J.S. Structural characterization of zinc-deficient human superoxide dismutase and implications for ALS. J. Mol. Biol. 2007, 373:877-890.
187. Yim M.B., Kang J.H., Yim H.S., Kwak H.S., Chock P.B., Stadtman E.R. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5709-5714.
188. Liu H., Zhu H., Eggers D.K., Nersissian A.M., Faull K.F., Goto J.J., Ai J., Sanders-Loehr J., Gralla E.B., Valentine J.S. Copper(2+) binding to the surface residue cysteine 111 of His46Arg human copper-zinc superoxide dismutase, a familial amyotrophic lateral sclerosis mutant. Biochemistry 2000, 39:8125-8132.
189. Watanabe S., Nagano S., Duce J., Kiaei M., Li Q.X., Tucker S.M., Tiwari A., Brown R.H., Beal M.F., Hayward L.J., Culotta V.C., Yoshihara S., Sakoda S., Bush A.I. Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2007, 42:1534-1542.
190. Mukhopadhyay C.K., Mazumder B., Lindley P.F., Fox P.L. Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:11546-11551.
191. Kiaei M., Bush A.I., Morrison B.M., Morrison J.H., Cherny R.A., Volitakis I., Beal M.F., Gordon J.W. Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004, 24:7945-7950.
192. Burstein E., Ganesh L., Dick R.D., van De S.B., Wilkinson J.C., Klomp L.W., Wijmenga C., Brewer G.J., Nabel G.J., Duckett C.S. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J. 2004, 23:244-254.
193. Mufti A.R., Burstein E., Csomos R.A., Graf P.C., Wilkinson J.C., Dick R.D., Challa M., Son J.K., Bratton S.B., Su G.L., Brewer G.J., Jakob U., Duckett C.S. XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol. Cell 2006, 21:775-785.
194. Pasinelli P., Belford M.E., Lennon N., Bacskai B.J., Hyman B.T., Trotti D., Brown R.H. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004, 43:19-30.
195. Higgins C.M., Jung C., Ding H., Xu Z. Mutant Cu-Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J. Neurosci. 2002, 22:RC215.
196. Okado-Matsumoto A., Fridovich I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9010-9014.
197. Ji H.F., Shen L., Zhang H.Y. Beta-lactam antibiotics are multipotent agents to combat neurological diseases. Biochem. Biophys. Res. Commun. 2005, 333:661-663.
198. Petri S., Calingasan N.Y., Alsaied O.A., Wille E., Kiaei M., Friedman J.E., Baranova O., Chavez J.C., Beal M.F. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2007, 102:991-1000.
199. Hottinger A.F., Fine E.G., Gurney M.E., Zurn A.D., Aebischer P. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 1997, 9:1548-1551.
200. Andreassen O.A., Dedeoglu A., Klivenyi P., Beal M.F., Bush A.I. N-acetyl-l-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000, 11:2491-2493.
201. Andreassen O.A., Dedeoglu A., Friedlich A., Ferrante K.L., Hughes D., Szabo C., Beal M.F. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. 2001, 168:419-424.
202. Nagano S., Ogawa Y., Yanagihara T., Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci. Lett. 1999, 265:159-162.
203. Nagano S., Fujii Y., Yamamoto T., Taniyama M., Fukada K., Yanagihara T., Sakoda S. The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp. Neurol. 2003, 179:176-180.
204. Wiedau-Pazos M., Goto J.J., Rabizadeh S., Gralla E.B., Roe J.A., Lee M.K., Valentine J.S., Bredesen D.E. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996, 271:515-518.
205. Azzouz M., Poindron P., Guettier S., Leclerc N., Andres C., Warter J.M., Borg J. Prevention of mutant SOD1 motoneuron degeneration by copper chelators in vitro. J. Neurobiol. 2000, 42:49-55.
206. Ogra Y., Suzuki K.T. Targeting of tetrathiomolybdate on the copper accumulating in the liver of LEC rats. J. Inorg. Biochem. 1998, 70:49-55.
207. Wild E.J., Tabrizi S.J. Huntington's disease phenocopy syndromes. Curr. Opin. Neurol. 2007, 20:681-687.
208. Fox J.H., Kama J.A., Lieberman G., Chopra R., Dorsey K., Chopra V., Volitakis I., Cherny R.A., Bush A.I., Hersch S. Mechanisms of copper ion mediated Huntington's disease progression. PLoS ONE 2007, 2:e334.
209. The Huntington's Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell 72 (1993) 971-983.
210. Velier J., Kim M., Schwarz C., Kim T.W., Sapp E., Chase K., Aronin N., DiFiglia M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 1998, 152:34-40.
211. Hilditch-Maguire P., Trettel F., Passani L.A., Auerbach A., Persichetti F., MacDonald M.E. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 2000, 9:2789-2797.
212. Garcia M., Charvin D., Caboche J. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 2004, 127:859-870.
213. Wild E.J., Tabrizi S.J. The differential diagnosis of chorea. Pract. Neurol. 2007, 7:360-373.
214. Schapira A., Lodi R. Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Methods Mol. Biol. 2004, 277:293-307.
215. Bartzokis G., Lu P.H., Tishler T.A., Fong S.M., Oluwadara B., Finn J.P., Huang D., Bordelon Y., Mintz J., Perlman S. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 2007, 32:1655-1664.
216. Bartzokis G., Cummings J., Perlman S., Hance D.B., Mintz J. Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 1999, 56:569-574.
217. de la Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47:516-525.
218. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
219. Chen J.C., Hardy P.A., Kucharczyk W., Clauberg M., Joshi J.G., Vourlas A., Dhar M., Henkelman R.M. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am. J. Neuroradiol. 1993, 14:275-281.
220. Cattaneo E., Zuccato C., Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6:919-930.
221. Zhang Y., Li M., Drozda M., Chen M., Ren S., Mejia Sanchez R.O., Leavitt B.R., Cattaneo E., Ferrante R.J., Hayden M.R., Friedlander R.M. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J. Neurochem. 2003, 87:101-106.
222. Pérez-Severiano F., Rios C., Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 2000, 862:234-237.
223. Hoffman K.E., Yanelli K., Bridges K.R. Ascorbic acid and iron metabolism: alterations in lysosomal function. Am. J. Clin. Nutr. 1991, 54:1188S-1192S.
224. Mehlhase J., Sandig G., Pantopoulos K., Grune T. Oxidation-induced ferritin turnover in microglial cells: role of proteasome. Free Radic. Biol. Med. 2005, 38:276-285.
225. Aziz N., Munro H.N. Iron regulates ferritin mRNA translation through a segment of its 5' untranslated region. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:8478-8482.
226. Hansen T.M., Nielsen H., Bernth N., Moos T. Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain. Brain Res. Mol. Brain Res. 1999, 65:186-197.
227. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
228. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
229. Meade C.A., Deng Y.P., Fusco F.R., Del M.N., Hersch S., Goldowitz D., Reiner A. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp. Neurol. 2002, 449:241-269.
230. Myers R.H., Vonsattel J.P., Paskevich P.A., Kiely D.K., Stevens T.J., Cupples L.A., Richardson E.P., Bird E.D. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J. Neuropathol. Exp. Neurol. 1991, 50:729-742.
231. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 2004, 25:5-18.
232. Lumsden A.L., Henshall T.L., Dayan S., Lardelli M.T., Richards R.I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum. Mol. Genet. 2007, 16:1905-1920.
233. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
234. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
235. Lind M.I., Missirlis F., Melefors O., Uhrigshardt H., Kirby K., Phillips J.P., Söderhäll K., Rouault T.A. Of two cytosolic aconitases expressed in Drosophila, only one functions as an iron-regulatory protein. J. Biol. Chem. 2006, 281:18707-18714.
236. Ward R.J., Kuhn L.C., Kaldy P., Florence A., Peters T.J., Crichton R.R. Control of cellular iron homeostasis by iron-responsive elements in vivo. Eur. J. Biochem. 1994, 220:927-931.
237. Hausladen A., Fridovich I. Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J. Biol. Chem. 1994, 269:29405-29408.
238. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
239. Schapira A.H. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim. Biophys. Acta 1999, 1410:159-170.
240. •- in the production of HO.: in vitro and in vivo. Free Radic. Biol. Med. 1994, 16:29-33.
241. Grünewald T., Beal M.F. Bioenergetics in Huntington's disease. Ann. N. Y. Acad. Sci. 1999, 893:203-213.
242. 1H NMR spectroscopy. Neurology 1993, 43:2689-2695.
243. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998, 50:1357-1365.
244. Joshi J.G. Ferritin: intracellular regulator of metal availability. Metals and Oxidative Damage in Neurological Disorders 1997, 131-143. Plenum Press, New York. J.R. Connor (Ed.).
245. Firdaus W.J., Wyttenbach A., Giuliano P., Kretz-Remy C., Currie R.W., Arrigo A.P. Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J. 2006, 273:5428-5441.
246. Nguyen T., Hamby A., Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11840-11845.
247. Ferrada E., Arancibia V., Loeb B., Norambuena E., Olea-Azar C., Huidobro-Toro J.P. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy. Neurotoxicology 2007, 28:445-449.
248. Ehrnhoefer D.E., Duennwald M., Markovic P., Wacker J.L., Engemann S., Roark M., Legleiter J., Marsh J.L., Thompson L.M., Lindquist S., Muchowski P.J., Wanker E.E. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 2006, 15:2743-2751.
249. Zheng W., Xin N., Chi Z.H., Zhao B.L., Zhang J., Li J.Y., Wang Z.Y. Divalent metal transporter 1 is involved in amyloid precursor protein processing and Aβ generation. FASEB J. 2009, 23:4207-4217.
250. Kalaria R.N., Sromek S.M., Grahovac I., Harik S.I. Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease. Brain Res. 1992, 585:87-93.
251. +-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 2010, 58:488-494.
252. Song N., Jiang H., Wang J., Xie J.X. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J. Neurosci. Res. 2007, 35:3118-3126.
253. +-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 2004, 279:15240-15247.